Severe coronary artery calcification in patients with CKD increases the risk for heart failure, heart valve calcification, and progression to kidney failure.

The FDA panel voted against the approval of sotagliflozin for patients with type 1 diabetes and chronic kidney disease.

Investigators have identified a platelet count threshold that appears prognostic in patients with ESRD hospitalized in the ICU.

GLP-1 receptor agonist use in the perioperative period should be based on shared decision-making of patient and care teams ...

(HealthDay News) — In a clinical guideline issued by the American Heart Association and American Stroke Association and published online in Stroke, updated recommendations are presented for the ...

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with MASH and liver fibrosis.

(HealthDay News) — The fibrinogen-to-albumin ratio (FAR) is an independent risk factor for development of any preeclampsia (PE) and PE with severe features (sPE), according to a study presented at the ...

(HealthDay News) — Restaging magnetic resonance imaging (MRI) can predict organ preservation and survival with rectal cancer, according to a study published online in Radiology.

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

FDA approved Orlynvah for the Tx of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.